Abstract
In the late 1970s and the early 1980s the initial p38 chemotype, the triaryl imidazoles, was discovered as an off-target effect during the development of cyclooxygenase and 5-lipoxygenase inhibitors long before the identity of the p38 kinase was known. During the last 10 years a number of novel p38 chemotypes were discovered via high throughput screening. More recently, the first series of p38 inhibitors discovered by xray crystallographic and virtual screening was announced. Finally, throughout the life span of p38 drug discovery programs significant medicinal chemistry effort has continually been placed on the design of new inhibitors from known chemotypes using molecular modeling, protein crystallography, hybrid design and simply sound intuition. Indeed, the search for p38 kinase inhibitors offers an excellent historical perspective as to how technological changes that have taken place in the pharmaceutical industry over the last decade, have affected the ways in which new leads are discovered and advanced. It is the intent of this review to highlight the discoveries of novel p38 chemotypes, emphasizing where possible the key technologies used in the discoveries and the knowledge gained from each discovery.
Keywords: triaryl imidazoles, p inhibitors, skf, atp binding site, combinatorial libraries, amino-methylbenzamide, epidermal growth factor receptor
Current Topics in Medicinal Chemistry
Title: The Discovery of Novel Chemotypes of p38 Kinase Inhibitors
Volume: 5 Issue: 10
Author(s): David J. Diller, Tsung H. Lin and Axel Metzger
Affiliation:
Keywords: triaryl imidazoles, p inhibitors, skf, atp binding site, combinatorial libraries, amino-methylbenzamide, epidermal growth factor receptor
Abstract: In the late 1970s and the early 1980s the initial p38 chemotype, the triaryl imidazoles, was discovered as an off-target effect during the development of cyclooxygenase and 5-lipoxygenase inhibitors long before the identity of the p38 kinase was known. During the last 10 years a number of novel p38 chemotypes were discovered via high throughput screening. More recently, the first series of p38 inhibitors discovered by xray crystallographic and virtual screening was announced. Finally, throughout the life span of p38 drug discovery programs significant medicinal chemistry effort has continually been placed on the design of new inhibitors from known chemotypes using molecular modeling, protein crystallography, hybrid design and simply sound intuition. Indeed, the search for p38 kinase inhibitors offers an excellent historical perspective as to how technological changes that have taken place in the pharmaceutical industry over the last decade, have affected the ways in which new leads are discovered and advanced. It is the intent of this review to highlight the discoveries of novel p38 chemotypes, emphasizing where possible the key technologies used in the discoveries and the knowledge gained from each discovery.
Export Options
About this article
Cite this article as:
Diller J. David, Lin H. Tsung and Metzger Axel, The Discovery of Novel Chemotypes of p38 Kinase Inhibitors, Current Topics in Medicinal Chemistry 2005; 5 (10) . https://dx.doi.org/10.2174/1568026054985948
DOI https://dx.doi.org/10.2174/1568026054985948 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews The Surgical Treatment of Diabetic Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Sites of Action of HIV-1 Vpu in BST-2/Tetherin Downregulation
Current HIV Research Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews The Therapeutic Potential of Neural Stem Cells in Cerebral Ischemia
Current Signal Transduction Therapy Treatment Strategies Against Psoriasis: Principle, Perspectives and Practices
Current Drug Delivery Demonstration of the Efficacy of Statins in Resolution of Plaque Inflammation by Serial FDG Imaging
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) New Therapies for the Treatment of Chronic Hepatitis C
Current Pharmaceutical Design Mechanisms of CTLA-4-Ig in Tolerance Induction
Current Pharmaceutical Design Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Current Proteomics The Promise of Antimicrobial Peptides for Treatment of Human Schistosomiasis
Current Drug Targets Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Current Drug Targets Therapeutic Approaches for COVID-19 Based on the Interferon-Mediated Immune Responses
Current Signal Transduction Therapy Endocannabinoids: A New Family of Lipid Mediators Involved in the Regulation of Neural Cell Development
Current Pharmaceutical Design Mast Cells in Abdominal Aortic Aneurysms
Current Vascular Pharmacology Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design Effect of Cytostatic Drugs on the mRNA Expression Levels of Ribonuclease κ in Breast and Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds